Zacks Investment Research upgraded shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) from a sell rating to a hold rating in a research note published on Monday.

According to Zacks, “Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States. “

A number of other research firms have also recently commented on ELOX. SunTrust Banks assumed coverage on Eloxx Pharmaceuticals in a research report on Monday, June 25th. They set a buy rating and a $26.00 price objective for the company. Canaccord Genuity assumed coverage on Eloxx Pharmaceuticals in a research report on Friday, June 29th. They set a buy rating and a $24.00 price objective for the company. Finally, Citigroup assumed coverage on Eloxx Pharmaceuticals in a research report on Tuesday, July 3rd. They set a buy rating and a $31.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $25.25.

Eloxx Pharmaceuticals stock opened at $13.50 on Monday. Eloxx Pharmaceuticals has a one year low of $3.90 and a one year high of $24.60.

Eloxx Pharmaceuticals (OTCMKTS:ELOX) last posted its quarterly earnings data on Tuesday, August 7th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03).

Institutional investors and hedge funds have recently modified their holdings of the business. Menora Mivtachim Holdings LTD. purchased a new stake in Eloxx Pharmaceuticals in the second quarter worth about $29,247,000. Strs Ohio purchased a new stake in Eloxx Pharmaceuticals in the second quarter worth about $107,000. Emerald Mutual Fund Advisers Trust bought a new position in shares of Eloxx Pharmaceuticals in the second quarter worth about $3,414,000. Tower Research Capital LLC TRC bought a new position in shares of Eloxx Pharmaceuticals in the second quarter worth about $146,000. Finally, Rhumbline Advisers bought a new position in shares of Eloxx Pharmaceuticals in the second quarter worth about $337,000.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Featured Story: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on Eloxx Pharmaceuticals (ELOX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.